ArticleHuman vaccines & immunotherapeutics2025

Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma.

Jiefeng Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.